LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Crinetics Pharmaceuticals Inc

Închisă

SectorSănătate

29.7 -0.6

Rezumat

Modificarea prețului

24h

Curent

Minim

29.36

Maxim

30.8

Indicatori cheie

By Trading Economics

Venit

-16M

-97M

Vânzări

361K

361K

EPS

-1.04

Marjă de profit

-26,807.202

Angajați

437

EBITDA

-17M

-110M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+158.42% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-336M

2.8B

Deschiderea anterioară

30.3

Închiderea anterioară

29.7

Sentimentul știrilor

By Acuity

8%

92%

6 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 iun. 2025, 20:51 UTC

Câștiguri

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 iun. 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 iun. 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 iun. 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 iun. 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 iun. 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 iun. 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 iun. 2025, 18:39 UTC

Market Talk
Câștiguri

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 iun. 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 iun. 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 iun. 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 iun. 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 iun. 2025, 17:08 UTC

Câștiguri

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 iun. 2025, 16:52 UTC

Achiziții, Fuziuni, Preluări

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 iun. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 iun. 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 iun. 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

158.42% sus

Prognoză pe 12 luni

Medie 77.5 USD  158.42%

Maxim 97 USD

Minim 60 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

7

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

6 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.